Korean Drug Co. Ltd Working Capital to Net Assets Ratio
Korean Drug Co. Ltd working capital to net assets ratio. Korean Drug Co. Ltd (014570) has a Working Capital to Net Assets ratio of 73.8% as of June 2026. Working capital of ₩58.16 Billion (current assets of ₩75.34 Billion minus current liabilities of ₩17.18 Billion) is measured against net assets of ₩78.82 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Korean Drug Co. Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Korean Drug Co. Ltd (2014–2025)
Working capital to net assets ratio of Korean Drug Co. Ltd from 2014 to 2025. This chart shows how Korean Drug Co. Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at 73.8%, reflecting working capital of ₩58.16 Billion against net assets of ₩78.82 Billion KRW. See Korean Drug Co. Ltd (014570) defensive interval to measure how many days the company can operate on defensive assets alone.
Korean Drug Co. Ltd Working Capital to Net Assets Ratio by Year (2014–2025)
Korean Drug Co. Ltd working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Korean Drug Co. Ltd from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Korean Drug Co. Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 73.2% | ₩60.77 Billion | ₩83.07 Billion | ₩69.07 Billion | ₩8.29 Billion | ▲ +1.8 pp |
| 2024 | 71.3% | ₩55.72 Billion | ₩78.11 Billion | ₩62.93 Billion | ₩7.21 Billion | ▲ +1.9 pp |
| 2023 | 69.4% | ₩53.52 Billion | ₩77.09 Billion | ₩63.43 Billion | ₩9.90 Billion | ▼ -7.5 pp |
| 2022 | 77.0% | ₩65.20 Billion | ₩84.71 Billion | ₩72.62 Billion | ₩7.41 Billion | ▼ -1.4 pp |
| 2021 | 78.4% | ₩60.12 Billion | ₩76.69 Billion | ₩70.45 Billion | ₩10.33 Billion | ▲ +3.4 pp |
| 2020 | 75.0% | ₩53.18 Billion | ₩70.87 Billion | ₩62.96 Billion | ₩9.77 Billion | ▲ +7.2 pp |
| 2019 | 67.9% | ₩44.15 Billion | ₩65.05 Billion | ₩52.73 Billion | ₩8.58 Billion | ▼ -2.8 pp |
| 2018 | 70.7% | ₩44.37 Billion | ₩62.80 Billion | ₩50.93 Billion | ₩6.56 Billion | ▲ +0.2 pp |
| 2017 | 70.4% | ₩40.13 Billion | ₩56.97 Billion | ₩48.73 Billion | ₩8.60 Billion | ▲ +1.7 pp |
| 2016 | 68.7% | ₩36.89 Billion | ₩53.66 Billion | ₩44.92 Billion | ₩8.03 Billion | ▲ +2.1 pp |
| 2015 | 66.7% | ₩33.13 Billion | ₩49.68 Billion | ₩40.44 Billion | ₩7.31 Billion | ▼ -4.3 pp |
| 2014 | 71.0% | ₩34.64 Billion | ₩48.79 Billion | ₩43.95 Billion | ₩9.31 Billion | — |